5:52 PM
 | 
Jul 23, 2013
 |  BC Extra  |  Company News

FDA committee mixed on axial spondyloarthritis

FDA's Arthritis Advisory Committee voted to expand the label of one autoimmune drug to include axial spondyloarthritis but voted against expanding the label of a second drug to include the indication. The committee voted 7-6, with one abstention, in favor of approving an sBLA from UCB Group (Euronext:UCB) to expand the label of Cimzia certolizumab...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >